EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 314 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... October 3, 2024 Breast Cancer Survivor Says Mistletoe Injections Have Kept Her Cancer-Free For... December 9, 2019 SABR with Immunotherapy Significantly Improves Event-Free Survival in Patients with Newly... July 27, 2023 Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 Load more HOT NEWS Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... Cliff Collapse Kills Woman Celebrating Breast Cancer Victory and 2 of... 10 Ways You Can Nurture A More Sustainable Garden
